In conclusion, bevacizumab, as a monoclonal antibody targeting VEGF-A, has demonstrated significant clinical benefits in ovarian cancer treatment, particularly for high-risk and chemotherapy-resistant patients. The gene discussed is VEGFA; the disease is ovarian cancer.